Open label dose-escalation US study of oral anti-VEGF medication shows VA improvement ahead of Phase II trial
Clinical results data announced at the 15th EURETINA Congress meeting reported that patients receiving “X-82”, a tyrosine kinase inhibitor under development by Tyrogenex Inc, Florida,… Read More »Open label dose-escalation US study of oral anti-VEGF medication shows VA improvement ahead of Phase II trial